PubMed Health⌕ Search

Biomedical subjects

F Cornu

Publications and source records attributed to F Cornu.

At least 19 recordsLinked to original sources
PubMed2000

External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.

The LIAISON immunoassay analyser was tested in a multicentre evaluation performed by 8 laboratories. The analytes evaluated were CA 15-3, CA 19-9, CA 125II, AFP, CEA, NSE and PSA. Excellent results were obtained for within-run and between-run precision with most assays showing within-run CVs < 5% and between-run CVs between 4 and 8%. The linearity of all assays was acceptable, however, for PSA, NSE and CA 19-9 a recovery > 110% was obtained for some of the samples tested. None of the assays revealed a high-dose hook effect. Method comparisons were performed by using the routine method of the respective study centre. Results generally showed an acceptable agreement between the LIAISON system and the different methods of comparison. The reference ranges for all assays were found to be in accordance with data known from the literature. All assays showed similar results for serum, heparinised plasma and EDTA plasma. Additionally, two experiments were performed with only one of the analytes tested: the sample-to-sample carry-over, using the CA 19-9 assay (3.3 x 10(-6)-2.3 x 10(-5)) and the functional sensitivity for the PSA assay (0.2 ng/ml).

Biomarkers, Tumor↗
PubMed1998

[Gaucher's disease and enzyme replacement therapy].

Gaucher disease is an autosomal recessive genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Glucocerebroside then accumulates in macrophages (Gaucher cells), causing anemia, thrombocytopenia, organomegaly and major bone problems. Discovery of the enzyme deficiency by Brady in 1964, and subsequent extraction and partial deglycosylation of the native enzyme led to a treatment. 1,600 people out of 5,000 possible worldwide patients benefit from this drug. The 70 French treated patients (out of an estimated 200) show remarkable improvement.

Gaucher Disease↗
PubMed1992

Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III.

The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor. It belongs to receptor tyrosine kinase subclass III, which also includes the colony-stimulating factor I receptor (c-fms), platelet-derived growth factor receptors A and B (PDGFRA and PDGFRB), as well as FLT1 and FLT3/FLK2. c-kit and PDGFRA, c-fms and PDGFRB, FLT1 and FLT3/FLK2 are grouped by pair in three clusters in man on chromosome 4 band q11-q13, chromosome 5 band q31-q33 and chromosome 13 band q12 respectively. Here, we report the genomic organization of the human c-kit gene, which is composed of 21 small coding exons, distributed over 80 kb. Comparison of the c-kit and c-fms oncogenes shows that they share identified exon/intron boundaries in their two kinase domains, as well as a similar exon/intron organization in the extracytoplasmic domain. Comparison with the kinase domains of tyrosine kinase genes not belonging to subclass III suggests that the exon/intron organization of c-kit and c-fms is a characteristic feature of subclass III. The genomic similarities between c-kit and c-fms, in conjunction with the location in pairs on different chromosomes of the subclass III genes, has led us to hypothesize that cis and trans duplications gave rise to this group of genes.

Amino Acid Sequence↗
PubMed1987

HLA typing in heavily transfused haemophiliacs with or without antibodies against human immunodeficiency virus (HIV).

HLA-A, B, DR antigens were determined in 46 patients, heavily transfused with blood products. Patients were 44 haemophiliacs, one case of afibrinogenemia and one case of von Willebrand's disease. Thirty-three patients had HIV antibodies. No significant difference for HLA antigen frequencies was observed in haemophiliacs with or without HIV antibodies, nor between haemophiliacs and a control population.

Adolescent↗
PubMed1984

Efficacy and tolerability of dibenzepin administered by intravenous drip infusion to severely depressed patients.

46 severely depressed inpatients received 10-hour intravenous infusions supplying a dose of 720 mg dibenzepin daily on 2 or some cases 3 successive days. The patients were kept under close psychiatric surveillance and their cardiovascular function was carefully monitored. The shorter infusions were as effective as infusions of the same dose of Noveril over 48 h, and did not lead to a greater frequency or severity of general or cardiovascular side effects. The 10-hour infusion regimen thus represents a new mode of treatment for severe depression which is less demanding both technically and in terms of nursing care.

Administration, Oral↗
PubMed1978

[Transsexualism].

Explore the source record for details and available documents.

Diagnosis, Differential↗
PubMed1976

[Abstinence behavior and plasma concentration of disulfiram in alcoholics after esperal implantation].

Abstinence behaviour after disulfiram implantation has been investigated in 21 chronic alcoholics. The blood levels of disulfiram and its metabolites, carbon disulfide (CS2) and reduced disulfiram (diethyldithiocarbamate) were determined and the blood levels of patients with implants were compared with those of patients receiving disulfiram orally. The blood levels in the implanted patients were significantly lower than those of the group taking disulfiram orally. No metabolites were detectable after 3 months, despite the sensitive method employed. Nevertheless, 14 of the 21 chronic alcoholics remained abstinent for 6 months after implantation. This result is probably due in the main to psychotherapeutic guidance.

Adult↗